FDA Approves Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer
RegulatoryapprovedKeytrudaKeytruda QlexPadcevPositive
AI Analysis
Summary
The FDA approved Keytruda and Keytruda Qlex, each combined with Padcev, for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer in adults. This represents a significant approval expansion for Merck's pembrolizumab franchise in urothelial cancer.
Outcome Details
FDA approved Keytruda and Keytruda Qlex, each in combination with Padcev, for treatment before and after surgery in muscle-invasive bladder cancer
Importance:8/10
Sentiment:
0.90
FDA approvaloncologyimmuno-oncologybladder cancercombination therapyperioperative treatment
Read the original article
Published by Drugs.com New Drug Approvals on July 10, 2026 3:07 AM